Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility
用于治疗和改善严重不育男性纵向健康结果的新型表观遗传学测试
基本信息
- 批准号:10760354
- 负责人:
- 金额:$ 26.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-11 至 2024-02-02
- 项目状态:已结题
- 来源:
- 关键词:AffectAmericanAreaBiological AssayBiological SciencesBiopsyCardiovascular DiseasesChildChronicCollaborationsConceptionsCouplesDNADNA analysisDataDevelopmentDiagnosisDiagnostic testsEjaculationEpigenetic ProcessFailureFertilization in VitroFundingGeneticGenetic CounselingGenetic DiseasesGenetic ScreeningGrantHealthInfertilityKlinefelter&aposs SyndromeLaboratoriesLeftLinkLongevityMale InfertilityMalignant NeoplasmsMarketingMetabolic DiseasesMethodsMicrodissectionModelingMolecular AbnormalityOutcomePatientsPhysiciansPopulationProceduresProductionProtocols documentationReproductive HealthReproductive MedicineResearchRetrievalSamplingSeminalSeminal PlasmaSeminal fluidSeminiferous tubule structureSeveritiesSmall Business Innovation Research GrantSocietiesSolidTestingTestisUninsured Medical ExpenseUnited States National Institutes of HealthUniversitiesUnnecessary ProceduresY chromosome microdeletionsbisulfite sequencingcell free DNAclinically actionablecommercializationcostgenetic counselorgenetic testinghealth managementhigh riskimprovedinfertility treatmentinnovationinsightmalemale healthmenmicrodeletionneuropsychiatrynew technologynovelpoor health outcomeprognostic indicatorsperm cellsubfertilitysuccesszygote
项目摘要
NIH SBIR Fast-Track Application: Inherent Biosciences
SUMMARY/ABSTRACT
Title: Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for
Men with Severe Infertility
39.7 million men worldwide (1% of the male population) suffer the severest form of male
infertility: Non-Obstructive Azoospermia (NOA). These men have no identifiable sperm in their semen,
greatly limiting their chances of having children of their own. In addition to the heartbreak of infertility, these
men have been found to have much higher risks for many long-term health conditions including cancers,
metabolic diseases, and neuropsychiatric conditions. The lack of sperm is usually their earliest indication
of potential chronic and somatic concerns. Men presenting with NOA, according to the American Society of
Reproductive Medicine, should always be screened for genetic conditions (including Klinefelter’s Syndrome
and Y-chromosome microdeletions) and be directed to further genetic counseling if any are discovered.
There is essentially one path that can be taken for patients with NOA to retrieve sperm cells: testicular
biopsy procedures. Microdissection testicular sperm extraction (mTESE) is the most common testicular biopsy
procedure and is performed by cutting open the testicles and identifying areas in the seminiferous tubules with
possible pockets of sperm production. Sperm then can be removed from the tubules and used for fertilization
of an egg. mTESE is extremely invasive and expensive (~$12,000 out of pocket) and only has a 40-50%
success rate of finding any sperm.
To give these men the best options for conceiving and long term health management, the
Jenkins and Hill Laboratories at Brigham Young University (BYU), in collaboration with Inherent Biosciences
(Inherent), are developing a new, single comprehensive diagnostic test that 1) predicts the success of mTESE
with extreme accuracy to guide treatment of sperm retrieval and subsequent conception, 2) more accurately
identifies the subtypes of all Y-chromosome microdeletions (which is an important prognostic indicator), and 3)
identifies Klinefelter’s Syndrome. Termed NOA-guideTM, this diagnostic test will be available for use by all
NOA men (1% of the male population). NOA-guide will determine the presence (or absence) of
sperm-derived cfDNA in a semen sample to determine if sperm retrieval from the testicle is a viable
fertility treatment option for men diagnosed with NOA and will identify certain genetic abnormalities
causative of NOA.
All Aims and Tasks described in this proposal are based on solid preliminary data from both the Jenkins
and Hill laboratories. Additionally, the plan for commercialization and NOA-guide success are founded in
detailed financial models and market launch plans developed by Inherent Biosciences - a company ideally
situated to execute all aspects of this study. With the support of this NIH SBIR Fast-Track grant,
NOA-guide will provide physicians and patients with unprecedented insight into the chances of mTESE
success and the genetic abnormalities that may be causing NOA. Also, patients not suitable for mTESE
will avoid unnecessary invasive procedures and significant out-of-pocket expenses.
NIH SBIR快速通道申请:内在生物科学
总结/摘要
标题:治疗和改善纵向健康结局的新型表观遗传学测试
严重不育的男性
39.7全世界有100万男性(占男性人口的1%)患有最严重的男性性行为。
不孕症:非阻塞性无精子症(NOA)。这些人的精液中没有可识别的精子,
极大地限制了她们生育自己孩子的机会。除了不孕不育的心碎,这些
已经发现男性对于许多长期健康状况包括癌症具有高得多的风险,
代谢疾病和神经精神疾病。缺乏精子通常是他们最早的迹象
潜在的慢性病和躯体疾病根据美国医学会的数据,
生殖医学,应始终筛查遗传性疾病(包括克氏综合征
和Y染色体微缺失),并被引导到进一步的遗传咨询,如果有发现。
NOA患者基本上可以采取一种途径来检索精子细胞:睾丸
活检程序。显微解剖睾丸精子提取(mTESE)是最常见的睾丸活检
手术,并通过切开睾丸和识别曲细精管中的区域进行,
可能的精子生产的口袋。然后精子可以从小管中取出并用于受精
一个鸡蛋。mTESE是非常侵入性和昂贵的(约12,000美元的自掏腰包),只有40-50%
找到精子的成功率
为了给这些男人最好的选择怀孕和长期的健康管理,
杨百翰大学(BYU)的Jenkins和Hill实验室与Inherent Biosciences合作
(固有的),正在开发一种新的,单一的综合诊断测试,1)预测mTESE的成功
具有极高的准确性,以指导取精治疗和随后的受孕,2)更准确地
识别所有Y染色体微缺失的亚型(这是一个重要的预后指标),以及3)
确认了克氏综合征被称为NOA-guideTM,这种诊断测试将可供所有
NOA男性(占男性人口的1%)。”“
精液样品中的精子来源cfDNA,以确定从睾丸中取出的精子是否是可行的。
为诊断为NOA的男性提供生育治疗选择,并将确定某些遗传异常
NOA的原因。
本建议书中描述的所有目标和任务都基于Jenkins
希尔实验室此外,商业化计划和NOA指南的成功建立在
由Inherent Biosciences开发的详细财务模型和市场启动计划-一家理想的公司
能够执行本研究的各个方面。在NIH SBIR快速通道拨款的支持下,
NOA指南将为医生和患者提供前所未有的mTESE机会
成功和可能导致NOA的遗传异常。此外,不适合mTESE的患者
将避免不必要的侵入性手术和大量的自付费用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristin R Brogaard其他文献
A tissue specific atlas of gene promoter DNA methylation variability and the clinical value of its assessment
基因启动子DNA甲基化变异的组织特异性图谱及其评估的临床价值
- DOI:
- 发表时间:
2022 - 期刊:
- 影响因子:0
- 作者:
Ryan H. Miller;Chad A. Pollard;Kristin R Brogaard;Andrew Olson;L. Lipshultz;E. Johnstone;Yetunde Ibrahim;Jim Hotaling;E. Schisterman;S. Mumford;K. Aston;Timothy G. Jenkins - 通讯作者:
Timothy G. Jenkins
Systems Medicine and the Emergence of Proactive P4 Medicine: Predictive, Preventive, Personalized and Participatory
系统医学和主动 P4 医学的出现:预测性、预防性、个性化和参与性
- DOI:
10.1016/b978-0-12-385944-0.00023-x - 发表时间:
2013 - 期刊:
- 影响因子:3.2
- 作者:
L. Hood;M. Flores;Kristin R Brogaard;N. Price - 通讯作者:
N. Price
Kristin R Brogaard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristin R Brogaard', 18)}}的其他基金
Clinical epigenetic diagnostic for spermatogenic failure and future health risks
生精失败和未来健康风险的临床表观遗传学诊断
- 批准号:
10459080 - 财政年份:2022
- 资助金额:
$ 26.97万 - 项目类别:
相似海外基金
Asian American Community Cohort of the New York Metropolitan Area
纽约都会区亚裔美国人社区群体
- 批准号:
10724342 - 财政年份:2023
- 资助金额:
$ 26.97万 - 项目类别:
Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian American childhood cancer survivors
与亚裔/亚裔美国儿童癌症幸存者的生存护理相关的个人、文化和地区因素
- 批准号:
10693965 - 财政年份:2021
- 资助金额:
$ 26.97万 - 项目类别:
Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian American childhood cancer survivors
与亚裔/亚裔美国儿童癌症幸存者的生存护理相关的个人、文化和地区因素
- 批准号:
10482384 - 财政年份:2021
- 资助金额:
$ 26.97万 - 项目类别:
Individual, cultural, and area-based factors associated with survivorship care among Asian/Asian American childhood cancer survivors
与亚裔/亚裔美国儿童癌症幸存者的生存护理相关的个人、文化和地区因素
- 批准号:
10275095 - 财政年份:2021
- 资助金额:
$ 26.97万 - 项目类别:
Adaptation of the US-American pediatric Patient-Reported Outcome Measurement Information System (PROMIS) for the German speaking area
美国儿科患者报告结果测量信息系统 (PROMIS) 适应德语地区
- 批准号:
271504683 - 财政年份:2015
- 资助金额:
$ 26.97万 - 项目类别:
Research Grants
Transnationalism in American Studies and Future of Area Studies
美国研究中的跨国主义和区域研究的未来
- 批准号:
15K01898 - 财政年份:2015
- 资助金额:
$ 26.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluating Area-Based Socioeconomic Measures from American Community Survey data
根据美国社区调查数据评估基于地区的社会经济措施
- 批准号:
8565162 - 财政年份:2012
- 资助金额:
$ 26.97万 - 项目类别:
Doctoral Dissertation Improvement Grant: Clovis Settlement Behavior in the American Southeast: Using Lithic Artifact Analysis to Evaluate the Staging-Area Model
博士论文改进补助金:美国东南部的克洛维斯定居点行为:利用石器文物分析来评估集结区模型
- 批准号:
0852946 - 财政年份:2008
- 资助金额:
$ 26.97万 - 项目类别:
Standard Grant
Inter-American materials research - Thin film materials for large area encapsulation barriers for flexible organic electronics
美洲材料研究 - 用于柔性有机电子器件大面积封装屏障的薄膜材料
- 批准号:
312945-2005 - 财政年份:2007
- 资助金额:
$ 26.97万 - 项目类别:
Special Research Opportunity Program - Inter-American Collaboration in Materials Research
Inter-American materials research - Thin film materials for large area encapsulation barriers for flexible organic electronics
美洲材料研究 - 用于柔性有机电子大面积封装屏障的薄膜材料
- 批准号:
312945-2005 - 财政年份:2006
- 资助金额:
$ 26.97万 - 项目类别:
Special Research Opportunity Program - Inter-American Collaboration in Materials Research